Abstract 102P
Background
Acute lymphoblastic leukemia is the most common type of cancer among children. Around 20% of patients relapse after remission. Minimal residual disease (MRD) is used as a predictor of relapse. MDR is measured by flow cytometry in bone marrow samples. MicroRNAs are small non-coding RNAs that regulate gene expression, acting as oncogenic or tumor suppressor biomolecules. MicroRNAs are secreted in various biofluids, including urine or saliva, at levels that reflect the homeostatic state of an individual. These secreted microRNAs might be useful as non-invasive biomarkers of MRD and treatment follow up in leukemia. This study aims to identify and evaluate the usefulness of urinary and salivary microRNAs as biomarkers of MRD in children diagnosed with acute lymphoblastic leukemia.
Methods
Saliva and urine samples, from high (MRD≥10) and standard intermediate (MDR<10) risk of relapse children, were collected on day 15 of chemotherapy. MicroRNAs were extracted using a commercial kit and sequenced to identify differences in secretion patterns. Differential expression analysis was carried out using the DeSeq2 algorithm.
Results
The mean MRD on day 15 was 52.23 % ± 38.42 and 1.03 % ± 0.53 in the high risk and standard intermediate risk children, respectively. Twenty-three microRNAs were differentially secreted (adjusted p-value < 0.01 and log 2 fold change > 1) between the high risk and standard intermediate children in saliva (12 upregulated and 11 downregulated). In contrast, only 3 sequences were differentially secreted (all downregulated) in urine samples. The miR-1246 and miR-3976 showed the highest increase (log 2 fold change = 7.53) and decrease (log 2 fold change = -5.52), respectively, in saliva samples. In urine miR-4783-5p showed the highest decrease (log 2 fold change = -3.15). However, these results need to be validated using PCR techniques.
Conclusions
In conclusion, miR-1246, miR-3976 and miR-4783-5p show promising utility as MRD biomarkers for monitoring MRD and treatment follow up in children diagnosed with ALL. With the additional advantage that microRNAs are more stable than other molecular markers and urine and saliva samples are non-invasive and easy to collect.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
FONDECYT-CONCYTEC (Grant Contract Number 165-2020-FONDECYT).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract